Get all premium features to the best stock analysis tool

5AM Venture Management sold 170,000 shares of Praxis Precision Medicines in the fourth quarter. The quarter-end position value decreased by $9.01 million as a result of the move, which marked a full exit from Praxis.

Cormorant Asset Management sold 50,000 shares of PRAX in the fourth quarter; the estimated trade size was $9.31 million based on quarterly average pricing. Meanwhile, the quarter-end value of the PRAX position increased by $227.00 million, reflecting both trading and stock price appreciation.

Deerfield Management Company increased its PRAX stake by 62,500 shares in the fourth quarter; the estimated transaction value was $11.64 million based on quarterly average prices. Meanwhile, the quarter-end value of the PRAX position rose by $221.69 million, reflecting both the share addition and price appreciation during the period.

Driehaus Capital Management added 432,510 shares of PRAX in the fourth quarter; the estimated value of the transaction was $80.54 million. Meanwhile, the quarter-end position value rose by $248.48 million, reflecting both share purchases and stock price movement.

Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Baker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing.